Skip to main content
Erschienen in:

30.05.2024 | Original article

The effect of greater occipital nerve block on amplification of somatic symptoms and anxiety and depression levels in chronic migraine

verfasst von: Oruç Şahin, Muzaffer Güneş, Emine Hande Kılıçaslan Şahin, Recep Dönmez

Erschienen in: Acta Neurologica Belgica | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Objectives

It is known that chronic migraine (CM) is often accompanied by anxiety, depression, and psychosomatic complaints. We designed this study with the assumption that greater occipital nerve (GON) block treatment could potentially improve not only pain symptoms but also psychosomatic complaints. This study aimed to evaluate the changes in the visual analog scale (VAS), somatosensory amplification scale (SSAS), beck depression ınventory (BDI), and beck anxiety ınventory (BAI) with GON block treatment in patients with CM.

Methods

This study was conducted retrospectively on 164 patients with CM between December 2018 and January 2023. Patients underwent six sessions of GON block treatment at weeks 0, 1, 2, 3, 5, and 7. VAS, SSAS, BAI, and BDI scores; number of attacks per month (NAM); attack pain duration (APD); and monthly use of analgesics (UA) were compared before the start and at week 8 of GON block treatment.

Results

The mean age of the subjects was 38 ± 9 years. Statistical analysis revealed that VAS, SSAS, BAI, and BDI scores; NAM; APD; and monthly UA were statistically significantly lower following GON block treatment than before GON block treatment (p < 0.001 each).

Conclusion

GON block treatment was effective for pain and somatic complaints (amplification of physical symptoms), anxiety, and depressive symptoms accompanying CM in patients with CM.
Literatur
1.
Zurück zum Zitat Vincent M (2018) Headache classification committee of the international headache society (IHS) the international classification of headache disorders. Cephalalgia 38(1):201–211 Vincent M (2018) Headache classification committee of the international headache society (IHS) the international classification of headache disorders. Cephalalgia 38(1):201–211
2.
Zurück zum Zitat Seddik AH, Branner JC, Ostwald DA, Schramm SH, Bierbaum M, Katsarava Z (2020) The socioeconomic burden of migraine: an evaluation of productiosvity losses due to migraine headaches based on a low population study in Germany. Cephalalgia 40:1551–1560CrossRefPubMed Seddik AH, Branner JC, Ostwald DA, Schramm SH, Bierbaum M, Katsarava Z (2020) The socioeconomic burden of migraine: an evaluation of productiosvity losses due to migraine headaches based on a low population study in Germany. Cephalalgia 40:1551–1560CrossRefPubMed
3.
Zurück zum Zitat Stokes M, Becker WJ, Lipton RB et al (2011) Cost of health care among patients with chronic and episodic igraine in 916 Canada and the USA: results from the Internati-to onal burden of migraine study (IBMS). Headache 51:1058–1077CrossRefPubMed Stokes M, Becker WJ, Lipton RB et al (2011) Cost of health care among patients with chronic and episodic igraine in 916 Canada and the USA: results from the Internati-to onal burden of migraine study (IBMS). Headache 51:1058–1077CrossRefPubMed
4.
Zurück zum Zitat McLean G, Mercer SW (2017) Chronic migraine, comorbidity, and socioeconomic deprivation: cross-sectional analysis of a large nationally representative primary care database. J Comorb 7:89–95CrossRefPubMedPubMedCentral McLean G, Mercer SW (2017) Chronic migraine, comorbidity, and socioeconomic deprivation: cross-sectional analysis of a large nationally representative primary care database. J Comorb 7:89–95CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Cengiz GF, Sacmacı H, Aktürk T, Hacımusalar Y (2019) Comparison of patients with migraine and tension-type headache in terms of somatosensory amplification and health anxiety. Arq Neuropsiquiatr 77:768–774CrossRefPubMed Cengiz GF, Sacmacı H, Aktürk T, Hacımusalar Y (2019) Comparison of patients with migraine and tension-type headache in terms of somatosensory amplification and health anxiety. Arq Neuropsiquiatr 77:768–774CrossRefPubMed
6.
Zurück zum Zitat Maizels M, Burchette R (2004) Somatic symptoms in headache patients: the influence of headache diagnosis, frequency, and comorbidity. Headache: J Head Face Pain 44(10):983–993CrossRef Maizels M, Burchette R (2004) Somatic symptoms in headache patients: the influence of headache diagnosis, frequency, and comorbidity. Headache: J Head Face Pain 44(10):983–993CrossRef
9.
Zurück zum Zitat Chowdhury D, Mundra A (2020) Role of greater occipital nerve block for preventive treatment of chronic migraine: a critical review. Cephalalgia rep 3:1–20 Chowdhury D, Mundra A (2020) Role of greater occipital nerve block for preventive treatment of chronic migraine: a critical review. Cephalalgia rep 3:1–20
10.
Zurück zum Zitat Demirel EA, Karpuz B, Özdemir S et al (2021) Effectiveness of greater occipital nerve blocks in chronic migraine. J Surg Med 5(6):593–596CrossRef Demirel EA, Karpuz B, Özdemir S et al (2021) Effectiveness of greater occipital nerve blocks in chronic migraine. J Surg Med 5(6):593–596CrossRef
11.
Zurück zum Zitat İnan N, İnan LE, Coşkun Ö, Tunç T, İlhan M (2016) Effectiveness of greater occipital nerve blocks in migraine prophylaxis. Arch Neuropsychiatr 53:45–48CrossRef İnan N, İnan LE, Coşkun Ö, Tunç T, İlhan M (2016) Effectiveness of greater occipital nerve blocks in migraine prophylaxis. Arch Neuropsychiatr 53:45–48CrossRef
12.
Zurück zum Zitat Piovesan E, Kowacs P, Tatsui C, Lange M, Ribas L, Werneck L (2001) Referred pain after painful stimulation of the greater occipital nerve in humans: evidence of convergence of cervical afferences on trigeminal nuclei. Cephalalgia 21(2):107–109CrossRefPubMed Piovesan E, Kowacs P, Tatsui C, Lange M, Ribas L, Werneck L (2001) Referred pain after painful stimulation of the greater occipital nerve in humans: evidence of convergence of cervical afferences on trigeminal nuclei. Cephalalgia 21(2):107–109CrossRefPubMed
13.
Zurück zum Zitat Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB (2013) Psychiatric comorbidities of episodic and chronic migraine. J Neurol 260:1960–1969CrossRefPubMed Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB (2013) Psychiatric comorbidities of episodic and chronic migraine. J Neurol 260:1960–1969CrossRefPubMed
15.
16.
Zurück zum Zitat Guy W (1976) Clinical global impressions. In: Guy W (ed) ECDEU assessment manual for psychopharmacology: Publication ADM 76–338. MD: National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, pp 217–222 Guy W (1976) Clinical global impressions. In: Guy W (ed) ECDEU assessment manual for psychopharmacology: Publication ADM 76–338. MD: National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, pp 217–222
17.
Zurück zum Zitat Hisli N (1988) A study on the validity of beck depression inventory. Turk J Psychol 6:118–122 Hisli N (1988) A study on the validity of beck depression inventory. Turk J Psychol 6:118–122
18.
Zurück zum Zitat Kılınç S, Torun F (2011) Depression rating scales used in clinical practice in Turkey. J Dirim Med 86(1):39–47 Kılınç S, Torun F (2011) Depression rating scales used in clinical practice in Turkey. J Dirim Med 86(1):39–47
19.
Zurück zum Zitat Ulusoy M, Sahin NH, Erkmen H (1998) Turkish version of the beck anxiety inventory: psychometric properties. J Cogn Psychother 12(2):163 Ulusoy M, Sahin NH, Erkmen H (1998) Turkish version of the beck anxiety inventory: psychometric properties. J Cogn Psychother 12(2):163
20.
Zurück zum Zitat Barsky AJ, Wyshak G, Klerman GL (1990) The somatosensory amplification scale and its relationship to hypochondriasis. J Psychiatry Res 24:323–334CrossRef Barsky AJ, Wyshak G, Klerman GL (1990) The somatosensory amplification scale and its relationship to hypochondriasis. J Psychiatry Res 24:323–334CrossRef
21.
Zurück zum Zitat Güleç H, Sayar K, Güleç MY (2007) The reliability and validity of the turkish form of the somatosensory amplification scale. Dusunen Adam J Psychiatry Neurol Sci 20(1):16–24 Güleç H, Sayar K, Güleç MY (2007) The reliability and validity of the turkish form of the somatosensory amplification scale. Dusunen Adam J Psychiatry Neurol Sci 20(1):16–24
22.
Zurück zum Zitat Vos T, Barber RM, Bell B et al (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet 386(9995):743–800CrossRef Vos T, Barber RM, Bell B et al (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet 386(9995):743–800CrossRef
24.
Zurück zum Zitat Aronson KR, Barrett LF, Quigley KS (2001) Feeling your body or feeling badly: evidence for the limited validity of the somatosensory amplification scale as an index of somatic sensitivity. J Psychosom Res 51:387–394CrossRefPubMed Aronson KR, Barrett LF, Quigley KS (2001) Feeling your body or feeling badly: evidence for the limited validity of the somatosensory amplification scale as an index of somatic sensitivity. J Psychosom Res 51:387–394CrossRefPubMed
25.
Zurück zum Zitat Kosturek A, Gregory RJ, Sousou AJ, Trief P (1998) Alexithymia and somatic amplification in chronic pain. Psychosomatics 39:399–404CrossRefPubMed Kosturek A, Gregory RJ, Sousou AJ, Trief P (1998) Alexithymia and somatic amplification in chronic pain. Psychosomatics 39:399–404CrossRefPubMed
26.
Zurück zum Zitat Sayar K, Kirmayer LJ, Taillefer SS (2003) Predictors of somatic symptoms in depressive disorder. Gen Hosp Psychiatry 25:108–114CrossRefPubMed Sayar K, Kirmayer LJ, Taillefer SS (2003) Predictors of somatic symptoms in depressive disorder. Gen Hosp Psychiatry 25:108–114CrossRefPubMed
27.
Zurück zum Zitat Gopaldas M, Zanderigo F, Zhan S et al (2019) Brain serotonin transporter binding, plasma arachidonic acid and depression severity: a positron emission tomography study of major depression. J Affect Disord 257:495–503CrossRefPubMedPubMedCentral Gopaldas M, Zanderigo F, Zhan S et al (2019) Brain serotonin transporter binding, plasma arachidonic acid and depression severity: a positron emission tomography study of major depression. J Affect Disord 257:495–503CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Metin KM, Dilek SS, Karaduman Y, Serçe A, Takmaz SA, İnan LE (2023) The effects of greater occipital nerve blockage with lidocaine on sleep characteristics in chronic migraine patients. Clin Neurol Neurosurg 231:107826CrossRefPubMed Metin KM, Dilek SS, Karaduman Y, Serçe A, Takmaz SA, İnan LE (2023) The effects of greater occipital nerve blockage with lidocaine on sleep characteristics in chronic migraine patients. Clin Neurol Neurosurg 231:107826CrossRefPubMed
29.
Zurück zum Zitat Vigano A, Torrieri MC, Toscano M et al (2018) Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology. J Headache Pain 19:73–82CrossRefPubMedPubMedCentral Vigano A, Torrieri MC, Toscano M et al (2018) Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology. J Headache Pain 19:73–82CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Inan LE, Inan N, Karadas O et al (2015) Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. Acta Neurol Scand 132:270–277CrossRefPubMed Inan LE, Inan N, Karadas O et al (2015) Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. Acta Neurol Scand 132:270–277CrossRefPubMed
31.
Zurück zum Zitat Gul H, Ozon A, Karadas O, Koc G, Inan LE (2017) The efficacy of greater occipital nerve blockade in chronic migraine: a placebo-controlled study. Acta Neurol Scand 136(2):138–144CrossRefPubMed Gul H, Ozon A, Karadas O, Koc G, Inan LE (2017) The efficacy of greater occipital nerve blockade in chronic migraine: a placebo-controlled study. Acta Neurol Scand 136(2):138–144CrossRefPubMed
32.
Zurück zum Zitat Palamar D, Uluduz D, Saip S, Erden G, Unalan H, Akarirmak U (2015) Ultrasound-guided greater occipital nerve block: an efficient technique in chronic refractory migraine without aura? Pain Physician 18:153–162CrossRefPubMed Palamar D, Uluduz D, Saip S, Erden G, Unalan H, Akarirmak U (2015) Ultrasound-guided greater occipital nerve block: an efficient technique in chronic refractory migraine without aura? Pain Physician 18:153–162CrossRefPubMed
Metadaten
Titel
The effect of greater occipital nerve block on amplification of somatic symptoms and anxiety and depression levels in chronic migraine
verfasst von
Oruç Şahin
Muzaffer Güneş
Emine Hande Kılıçaslan Şahin
Recep Dönmez
Publikationsdatum
30.05.2024
Verlag
Springer International Publishing
Erschienen in
Acta Neurologica Belgica / Ausgabe 5/2024
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-024-02585-y

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Neurologie

Demenz-Leitlinie aktualisiert

  • 13.03.2025
  • Demenz
  • Nachrichten

Empfohlen wird jetzt auch eine Musiktherapie sowie bei unklarem diagnostischem Befund ein Tau-PET, und Depressive mit leichten kognitiven Störungen sollten eine Verhaltenstherapie erhalten – das sind einige wichtige Änderungen der aktuellen S3-Leitlinie Demenzen.

Frauen akkumulieren Tau-Protein schneller als Männer

Frauen mit einer hohen Beta-Amyloid-Last im Gehirn aggregieren mehr Tau-Protein als Männer mit vergleichbaren Amyloidwerten. Ähnliches gilt für Frauen mit einem ApoE4-Allel. Dafür sprechen die Daten einer Metaanalyse von Menschen im präklinischen Alzheimerstadium.

Frauen mit Apoplex in Deutschland nicht benachteiligt – oder doch?

Eine Analyse von Daten des statistischen Bundesamtes spricht dafür, dass Frauen in der Schlaganfallbehandlung nicht benachteiligt sind. Im Detail bleiben aber Fragen offen.

MS-Medikamente absetzen: ab 60 Jahren eine Option

Wann können ältere MS-Kranke ihre krankheitsmodifizierende Therapie gefahrlos absetzen? Bisher lieferten kontrollierte Studien hier keine eindeutigen Antworten. Eine neue Auswertung der Studie DISCOMS deutet auf einen grenzwertigen Nutzen ab 60 Jahren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.